Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: A population-based time-series analysis

CMAJ. Canadian Medical Association Journal

Volumn 179, Issue 5, 2008, Pages 438-446

  Valiyeva, Elmira ^a,b,d   Herrmann, Nathan ^a,c   Rochon, Paula A ^a,b,d,e   Gill, Sudeep S ^b,f   Anderson, Geoffrey M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGED; ARTICLE; CANADA; DATA ANALYSIS; DEMENTIA; DRUG SAFETY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MALE; POPULATION; PRESCRIPTION; REGULATORY WARNING; TIME SERIES ANALYSIS;

EID: 50649116606     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.071540     Document Type: Article

References (29)

1. Hauptman PJ, Schnitzler MA, Swindle J, et al. Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA 2006;296:1877-84.
2. Kesselheim AS, Fischer MA, Avorn J. The rise and fall of Natrecor for congestive heart failure: implications for drug policy. Health Aff (Millwood) 2006;25:1095-102.
3. Shatin D, Gardner JS, Stergachis A, et al. Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants. Pharmacoepidemiol Drug Saf 2005;14:149-54.
4. Important drug safety information: Risperdal (risperidone) and cerebrovascular adverse events in placebo-controlled dementia trials [Dear Healthcare Professional letter from Janssen-Ortho]. Ottawa: Health Canada; 2002. Available: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2002/ risperdal_hpc-cps-eng.php (accessed 2008 May 5).
5. Zyprexa (olanzapine) and cerebrovascular adverse events in placebo-controlled elderly dementia trials [Dear Healthcare Professional letter from Eli Lilly]. Ottawa: Health Canada; 2004. Available: www.hc-sc.gc.ca/dhp- mps/medeff/advisoriesavis/prof/_2004/zyprexa_hpc-cps-eng.php (accessed 2008 May 5).
6. Increased mortality associated with the use of atypical antipsychotic drugs in elderly patients with dementia [Dear Healthcare Professional letter]. Ottawa: Health Canada; 2004. Available: www.hc-sc.gc.ca/dhp-mps/medeff/ advisories-avis/prof/_2005/atyp-antipsycho_hpc-cps-eng.php (accessed 2008 May 5).
7. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41.
8. Gill SS, Bronskill SE, Normand SLT, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146:775-86.
9. Levy AR, O'Brien BJ, Sellors G, et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003;10:67-71.
10. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005;330:445.
11. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27:299-309.
12. Katz LY, Kozyrskyj AL, Prior HJ, et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 2008;178:1005-11.
13. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000;284:3036-9.
14. Goldman SA. Communication of medical product risk: How effective is effective enough? Drug Saf 2004;27:519-34.
15. Edwards A, Elwyn G. Understanding risk and lessons for clinical risk communication about treatment preferences. Qual Health Care 2001;10(suppl I):i9-13.
16. US Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioral disturbances [public health advisory]. Washington (DC): Department of Health and Human Services; 2005. Available at: www.fda.gov/Cder/drug/advisory/antipsychotics.htm (accessed 2008 May 14).
17. Herrmann N, Gauthier S, Lysy P. Clinical practice guidelines for severe Alzheimer's disease. Alzheimer Demen 2007;3:385-97.
18. US Food and Drug Administration. Seroquel (quetiapine) tablets [letter]. Washinton (DC): Department of Health and Human Services; 2006. Available: www.fda.gov/cder/warn/2006/Seroquel_letter.pdf (accessed 2008 May 5).
19. Polinski JM, Wang PS, Fischer MA. Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Af (Millwood) 2007;26:750-60.
20. Marshall DA, Willison DJ, Grootendorst P, et al. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada. Health Policy 2007;84:1-13.
21. Ramsay CR, Matowe L, Grilli R, et al. Interrupted time series designs in health technology assessment: lessons from two reviews of behaviour change strategies. Int J Technol Assess Health Care 2003;19:613-23.
22. US Food and Drug Administration. 2003 safety alert - Risperdal (risperidone) [letter from Janssen Pharmaceutica Inc.]. Washington (DC): Department of Health and Human Services; 2003. Available: www.fda.gov/medwatch/ SAFETY/2003/risperdal.htm (accessed 2008 May 5).
23. US Food and Drug Administration. Warning about Zyprexa (olanzapine) [FDA Patient Safety News podcast, show no. 27]. Washington (DC): Department of Health and Human Services; May 2004. Available: www.accessdata.fda.gov/scripts/cdrh/ cfdocs/psn/transcript.cfm?show=27#6 (accessed 2008 May 5).
24. Duff G. Atypical antipsychotic drugs and stroke. London (UK): Department of Health; 2004. Available: www.info.doh.gov.uk/doh/embroadcast.nsf/ vwDiscussionAll/3D8DBB48B26FF90280256E520045977A (accessed 2008 May 5).
25. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia, meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43.
26. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167:1269-70.
27. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004;170:1395.
28. Rabins PV, Lyketsos CG. Antipsychotic drugs in dementia. What should be made of the risks? JAMA 2005;294:1963-5.
29. Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly. JAMA 2005;293:2462.